Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$125.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Biomarin Pharmaceutical Inc Updates On FY 2013 Revenue Guidance In Line With Analysts' Estimates-Conference Call


Tuesday, 7 May 2013 03:00pm EDT 

Biomarin Pharmaceutical Inc announced that for fiscal 2013, it expects revenues over $500 million. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $547 million for fiscal 2013. 

Company Quote

91.53
3.35 +3.80%
26 Dec 2014